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ess: palmieri@unimo.itSummary The aim of this paper was to evaluate the impact of breast-gland
remodelling, for cosmetic or functional purposes, on cancer incidence during long-
term post-surgical follow-up. We reviewed the literature investigating the ratio
between the amount of breast tissue resected and cancer incidence during follow-
up. Our analysis of the published data suggested that hypertrophic breast
remodelling decreases the risk of breast and other types of cancer in post-operative
patients. The actual risk reduction for patients over 40 years of age is related to the
weight of the surgical specimens during the previous operation. Our conclusions
support the use of breast-reduction surgery as a preventive measure in patients
complaining of symptomatic breast enlargement, especially those with a family
history of breast cancer.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Breast reduction (BR), or reduction mastoplasty, is
a plastic procedure based on different surgical
techniques, which aims to reduce the breast
volume when it is affecting the patient’s quality
of life.Elsevier Ltd. All rights reserve
4222483;
(B. Palmieri).In this work, we review the available clinical
studies (Tables 1 and 2), and attempt to outline
future developments of the BR technique that
could increase its cancer-preventive impact and
effectiveness.BR and cancer during long-term follow-up
The earliest report, by Lund et al.,1 described 1245
women aged between 20 and 70 years who hadd.
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Table 2 Breast cancer found at the time of reduction mammaplasty.
First author
(year)
N (average age) CF (number of
breast cancers
found among N)
CF and cancer location Follow-up
Petit16 (1997) 440 22 In RM, 20 occult 4.6% In lower and
central quadrants (70%)
Not explicitly
reported
Jansen5 (1998) 2576 4 Two cases not found preoperatively
by mammography and self-
examination
2 years free of
cancer
Tang8 (1999) 27,500 17 Breast cancer found at 49 years old
for women undergoing RM (average
age at diagnosis: 61 years old)
8 years
Brown6 (1999) 27,500 18 Breast cancer Average 6.5
years
Keleher17
(2003)
4 4 4 cases not found preoperatively by
mammography and self-
examination at M.D. Anderson
Cancer
1–6 months
B. Palmieri et al.478undergone BR in Denmark between 1943 and 1971
using different surgical procedures. The authors
observed 18 cases of breast cancer versus 30.28
expected cases, with a relative risk (RR)—defined
as the ratio between the observed and expected
cancers—of 0.39.
In the first 10 years of follow-up, five cases were
detected versus 7.11 expected cases, while after
10 years of follow-up, 13 cases were detected
versus 23.17 expected cases. The greatest cancer-
risk reduction was experienced by women who had
at least 600 g of tissue surgically removed
(RR ¼ 0.31; 95% confidence interval [CI)]
0.06–0.91).
Nine years later, Baasch et al.2 followed-up the
original study group of Lund et al. The authors
calculated the RR as 0.61 and supported the
previous observation that 600 g was the minimum
critical mass of resected tissue to achieve a
significant cancer-risk reduction.
In the above-mentioned long-term follow-up (19
years) of 1240 patients, 32 cancers were observed
versus 52.55 expected cancers. Women who under-
went surgery at the age of 20 had a more or less
increased, but not statistically significant, risk of
malignancy compared with the general population
or other age groups. In the Copenhagen series, a
30% reduction in risk was seen among women aged
between 21 and 40 years during long-term follow-
up. A total of 20.7% of the patients aged 40 years or
above were nulliparous compared with 20% of the
general population; in addition, the mean number
of children was 1.7 and the mean age at the first
birth was 24.0 years, both of which were similar tothe figures for the general population. The long-
term follow-up did not show any specific trend
towards cancerisation. The population compliance
with X-ray screening to detect preoperative small
cancers in women aged over 50 years could explain
the substantial reduction in tumour incidence
during the 5-year follow-up (two versus 12 ex-
pected, while no such effect was seen in those aged
under 50 years (12 cancers observed versus 12.2
expected. Significant variation was seen depending
on the type of technique, date of operation, place
of surgery and quadrant.
Regarding the relationship between cancer in-
cidence and age, it should be noted that the
younger women tended to be slimmer and have
larger breasts than the older women; that is, the
older women were often overweight or obese. This
may have increased the risk of tumourigenesis and
also the protection offered by BR surgery. In fact,
surgery not only reduced the glandular mass that
could potentially become malignant, but also
removed a large number of adipocytes in the fat
tissue, which are responsible for enhancing the
hormonal co-carcinogenic potential by transform-
ing androstenedione into estrogens via aromatase.
Brinton et al.3 carried out a small population-
based case–control study on BR and cancer, which
formed part of an investigation into surgical breast
enlargement that included 2174 patients and 2009
controls with previous breast implants, 10 reduc-
tive mammoplasties and 13 controls. In the
prosthesis group, the observed percentage of
cancers—36 cases (11%) versus 44 (2%)—of the
controls showed a reduction in the RR of 0.2 and an
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Breast reduction and subsequent cancer 479RR value of 0.8 for both localised and distant
tumours; the reduction of risk in reductive masto-
plasties was 0.7% (95% CI 0.4–1.0).
Boice et al.4 examined the Danish hospital
discharge registry records of 7720 women who
underwent BR between 1977 and 1992, with a
specific focus on the risk according to age and time
since surgery. The median age at time of surgery
was 46 years and the mean length of follow-up was
7.5 years. A total of 182 cancers of various types
were observed during the follow-up versus 209
expected tumours (standardised incidence ratio
[SIR] ¼ 0.9%; 95% CI 0.7–1.0). Specifically, breast
cancer was reduced by roughly 50% (29 observed
tumours versus 53.9 expected tumours; RR ¼ 0.54).
Patient age at surgery was a significant factor; the
risk was reduced at the age of 40 years and an
overall reduction of 70% was observed at 50 years
of age.
The types of cancer observed among these
patients were ductal carcinomas (65%), alveolar
cancers (19%) and ductal carcinoma in situ (DCIS;
16%).
Jansen et al.5, in a retrospective study of 2576
BRs, reported four cases (0.16%) of intra-operative
cancer detection that escaped routine mammogra-
phy, self-examination and physical examination by
the surgeons. This different rate of incidental
tumour discovery at the time of reduction surgery
might be explained on the basis of differences in
the accuracy of preoperative breast examinations.
Nearly 660 patients with pre-existing breast cancer
were subsequently found not to be at risk in terms
of the contralateral operated breast, which was
exposed to a high risk of cancer.
Brown et al.6 used the Canadian Institute for
Health databank to identify 30 137 women who
submitted to bilateral (94.7%) or unilateral (5.3%)
BR between 1979 and 1992. The final eligible cases
comprised 26,567 bilateral reductions and 933
unilateral reductions. Of the latter group, 412
patients had prior breast cancer, 314 patients had
prior or synchronous cancer, 87 patients (27.7%)
had specific breast cancer and 18 cases were
detected during the operation. Among the 26,567
women who underwent surgery, 101 cancers were
observed versus 165.8 expected cancers, yielding
an RR of 0.61 (95% CI 0.50–0.74). Regarding other
primary cancers, 285 cases were observed versus
372.5 expected cases, with an RR of 0.77 (95% CI
0.68–0.86).
Lung cancer, cervical carcinoma and non-color-
ectal gastrointestinal tract tumours were most
frequently observed and had clearly reduced risks
(0.59, 0.51 and 0.58, respectively). These bene-
ficial effects were probably due to post-operativelifestyle changes, such as stopping smoking, in-
creasing physical activity and reducing body
weight.
Evaluating the breast cancer incidence during
the first 10 years post-operation, 86 cases
were observed versus 147 expected cases. The
remaining 15 cases occurred 10–14 years after
the initial surgery. Thus, the relative risk in the
first 10 years was 0.59 (95% CI 0.47–0.72), which
rose to 0.80 (95% CI 0.45–1.32) during the follo-
wing 4 years. No difference in risk was observed
between groups evaluated by age according to
decade.
Tang et al.7,8 reported on a cohort study of breast
cancer risk in BR patients (27,500 cases; 101
cancers detected) following a contemporary report
by Brown that showed a 40% reduction in the risk of
developing breast cancer after BR. In the retro-
spective survey, the author described the diagnosis
of cancer between 3 months and 13 years after
mammaplasty, with a median of 5 years. The
median age of the patients when they submitted
to reduction surgery was 50 years and the average
age at cancer detection was 55 years; this was
significantly younger than the average age of
cancer detection in the general population (61
years). This difference could be explained in terms
of the increased attention and awareness among
women who have undergone BR surgery, coupled
with the greater ease of physical and instrumental
exploration allowed by the reduced volume of
parenchyma. The histology and distribution were
similar to those of the control cases, as were the
surgical and oncological protocols employed. The
survival rate at 5 years was 70% in the breast-
reduction group and 77% in the control group; this
difference was not statistically significant, as
confirmed by the overlapping of the lower and
upper confidence levels.
Boice et al.9 investigated the oncologic impact of
BR on 31,910 women, excluding those with cancers
occurring before or within 3 months of surgery. The
mean age at surgery was 33 years and the mean
length of follow-up was 7.5 years. A total of 662
cancers were observed versus 729 expected cancers
(SIR ¼ 0.91; 95% CI 0.84–0.98) with a 28% breast
cancer reduction (161 detected versus 223 ex-
pected; SIR 0.72; 95% CI 0.61–0.84). Lung cancer
was also reduced (SIR ¼ 0.73) as was melanoma
(SIR ¼ 0.72). By contrast, corpus uteri cancer
(SIR ¼ 1.37), thyroid cancer (SIR ¼ 1.39), other
endocrine tumours (SIR ¼ 1.55) and parathyroid
adenomas (SIR ¼ 1.51) were all increased post-
operatively. In addition, the inverse association
between age at surgery and cancer risk was
confirmed in this study; in fact, the risk was
ARTICLE IN PRESS
B. Palmieri et al.480reduced by 24% and 43% in the groups aged 40–49
and over 50 years, respectively.
Brinton et al.10 focused their investigation on the
influence of the amount of tissue removed during
reduction mammoplasty on breast cancer risk. They
examined 137 BR specimens and 422 control
patients. Subjects who had more than 800 g of
tissue removed had a 76% lower risk relative to
those who had more than 400 g of tissue removed
from either breast, irrespective of age at surgery.
The weak protection from cancer observed in
patients who underwent surgery before the age of
40 years was probably related to the lower volume
of tissue removed, due to the relatively lower
weights of younger women compared with older
women; the genetic impact of cancer early in life
could also have had an effect. A longer follow-up
would therefore allow more accurate evaluation of
the effects on lifespan.Discussion
Our review identified a consensus in the literature,
that is, the removal of a critical amount of gland
and fat tissue significantly lowered the breast
cancer incidence in the operated cohort of patients
during long-term follow-up11–17 (Tables 1 and 2).
In addition, symmetric contralateral BR after
modified mastectomy and breast reconstruction of
the opposite site had an oncologically preventive
rationale. In fact, the increased cancer risk due to
exposure to potentially carcinogenic factors was
counteracted by gland-tissue subtraction.
When breast enlargement has reached a sympto-
matic clinical threshold, gland reduction should be
recommended not only as a restorative procedure
for the patient’s fitness and wellbeing, but also for
the effective removal of ageing gland tissue,
thereby preventing cancer onset.
Many women might submit to bilateral BR if the
oncologic prevention of a second primary cancer
could be achieved. Among the women who under-
went reduction mastoplasty, a cancer risk reduction
was also observed in terms of tumours affecting
other organs, such as the lung or GI tract. The
mechanism of the reduction in cancer risk due to
the removal of breast gland and fat tissue remains
unclear. However, changes in lifestyle, which are
probably related to improved self-esteem and
image, as well as the relief or disappearance of
arthro-muscular pain and discomfort, might give a
partial explanation of this phenomenon.
Under our developmental strategies, BR techni-
ques should aim for radical gland subtraction,
leaving no tissue in the nipple–areola complex(NAC), according to our previously described two-
step nipple-sparing subcutaneous mastectomy
technique,18 and remodelling the plentiful subcu-
taneous fat against the potential background of a
submuscular prosthesis. The problem of NAC
transposition (that is, uplifting the complex to-
gether with the newly formed dermal vascular
pedicle in order to achieve satisfying cosmetic
results) is a major issue, especially in large
hypertrophies where substantial NAC mobilisation
is required.
Another problem that requires careful intrao-
perative evaluation is the final operative field
overview in terms of removing all breast gland
remnants identified between the remaining fatty
tissues. This goal can be obtained by means of
transillumination and laparoscopic magnification.
In fact, consistent with the Beer et al. report,19 the
superficial fascia is not present in all breasts and
some ducto-alveolar clusters might not be visible
macroscopically, thus becoming the substrate for
carcinogenic agents during the follow-up, even if
the vascular network has been greatly reduced.
The challenge of transforming BR techniques into
cosmetic envelope mastectomy techniques with
immediate reconstruction is difficult but appealing.
It requires not only an adequate technical back-
ground and patient compliance from the cosmetic
point of view, but also the long-term follow-up of
case–control investigations.
However, owing to increased awareness, more
surgeons are expected to support the strategy of
appealing to middle-aged women in order to
improve their life quality, reduce breast cancer
incidence and enable more-effective instrumental
follow-up. Thus, a larger cohort of operated
patients with megalomastia or breast hypertrophy,
and some evidence of familial breast cancer or
genomic indicators, should be available in future.References
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